Lim, B., Jia, L., Sudheendra, P. K., Hirshfield, K. M. (2025). LITESPARK-029: A phase 2, randomized, open-label study of belzutifan plus fulvestrant in participants with estrogen receptor–positive, HER2-negative unresectable locally advanced or metastatic breast cancer after progression on previous endocrine therapy.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps1124